MarginsXMarginsX
Home › Markets › Health Care › FATE

Fate Therapeutics Inc. (FATE)

FATE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.14
-10.94% on the day
Market cap
$138.6M
Micro cap
Revenue · 2025
$6.6M
-51.2% on 2024
Net income · 2025
-$136.3M
-2051.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/0001193125-26-073699-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerFATE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2013
SEC CIK0001434316
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$6.6M
Net income-$136.3M
Operating income-$147.7M
Net margin-2051.1%
Operating margin-2222.4%
Revenue growth-51.2%
Cash$46.6M
Total assets$318.9M
P/E (computed)Net income was not positive
P/S (computed)20.9×

Warning signs

Cash runway
5.0 months
$43.9M cash at September 30, 2026
Share count, 1 year
+5.4%
2025-11-06 to 2026-10-30 · +23.3% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$323K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$43.9M cash; operating cash flow -$26.3M a quarter.Report 2026-09-30
Shares outstanding121,568,755 (2026-10-30); 115,352,289 a year earlier; 98,601,966 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $323K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$30.7M-$27.8M$43.9MNo debt tags$4.8M10-Q 2026-11-05
Q2 2026
2026-06-30
$2.1M-$30.2M-$23.4M$32.4MNo debt tags$6.5M10-Q 2026-08-13
Q1 2026
2026-03-31
$1.3M-$31.2M-$30.8M$39.6MNo debt tags$6.3M10-Q 2026-05-13
Q4 2025
2025-12-31
$1.4M-$32.4M-$23.3M$46.6MNo debt tags$6.6M10-K 2026-02-26
Q3 2025
2025-09-30
$1.7M-$32.3M-$24.4M$40.6MNo debt tags$7.1M10-Q 2026-11-05
Q2 2025
2025-06-30
$1.9M-$34.1M-$24.6M$41.2MNo debt tags$8.5M10-Q 2026-08-13
Q1 2025
2025-03-31
$1.6M-$37.6M-$33.8M$44.9MNo debt tags$13.3M10-Q 2026-05-13
Q4 2024
2024-12-31
$1.9M-$52.2M-$27.8M$36.1MNo debt tags$13.6M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-12
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 858 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-30.4%
1 month-36.0%
3 months-49.2%
Year to date+30.6%
1 year+29.3%
From 52-week high-58.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TARAProtara Therapeutics Inc.$2.38-5.93%$146.5M
HUMAHumacyte Inc.$0.5403-3.24%$150.1M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
STROSutro Biopharma Inc.$9.32-5.09%$154.7M
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier